Philip Morris
Who Will Regulate the Regulators? If You Make A Mistake, Shouldn't You Own Up? Not If You're the FDA, Epa, or Ftc
Fields
- Author
- Samuel, P.
- Area
- NICOLI,DAVID/OFFICE
- Type
- MAGA, MAGAZINE ARTICLE
- Attachment
- 2046936890/2046936892
- Named Organization
- Center for Devices + Radiological Health
- Centers for Disease Control
- Chemical Specialties Mfg Assn
- Cidex
- Congress
- Epa, Environmental Protection Agency
- FDA, Food and Drug Administration
- Federal Register
- Ftc, Federal Trade Commission
- Johnson Johnson
- Journal of Clinical Microbiology
- Journal of Operating Room Research
- Kafnesque
- Metrox
- Office of the Pesticides + Toxic Subst
- Sporicidin
- US Marshalls
- Usdc Co
- Walter Reed Army Medical Center
- Antimicrobial Programs Branch
- Centers for Disease Control
- Named Person
- Babcock, L.T.
- Kessler, D.
- Konzelman, J.
- Lee, J.H.
- Miner, N.
- Schattner, R.
- Ulatowski, T.
- Kessler, D.
- Document File
- 2046936725/2046937271/Missing
- Request
- Stmn/R1-072
- Stmn/R1-079
- Litigation
- Stmn/Produced
- Author (Organization)
- Natl Review
- Master ID
- 2046936726/6992
Related Documents:- 2046936726 Table of Contents
- 2046936727 A
- 2046936728-6731 FDA's Legally Suspect Actions Invite Challenge
- 2046936732-6735 FDA Paralysis Raises Health Care Costs
- 2046936736-6739 the Real Problem with Health Care in America: While Dr. David Kessler's FDA Fiddles, Medical Approvals Lag and Americans Die
- 2046936740-6743 What the FDA Doesn't Want You to Know Could Kill You
- 2046936744-6751
- 2046936752-6759
- 2046936760-6762 Guide to Medical Device Regulation FDA Issues First Warning Letter Citing Gmp Problems Under New Cpg
- 2046936763-6766 the Vitamin Uprising
- 2046936767-6780 Losing the Edge Overseas Patients Reap the Benefits of U.S.Research While Those Here Wait
- 2046936781-6783 Losing the Edge
- 2046936784 Feds: Toughen Regulation, Promote Research Improvements Needed, and They Are on the Way
- 2046936785-6786
- 2046936787-6789 Challenging FDA Authority
- 2046936790-6793 Speakeasies in A New Age of Prohibition
- 2046936794-6798 Who Is Happiest Politician in Washington Over Whitewater? Alfonse D'amato - Newt Gingrich - David Kessler?
- 2046936799-6800 Pro-Free Enterprise Group Challenges FDA's Authority to Regulate Drug Companies' Speech
- 2046936801-6802 Wlf Off-Label Use Suit Heats Up
- 2046936803-6805 Just Call Me 'doc'
- 2046936806-6810 Food and Drugs and Politics
- 2046936811-6813 Science and Technology Getting the Lead Out
- 2046936814 Forbes Fear of Falling 5 Ways to Protect Yourself in Scary Times
- 2046936815-6816 Book Burning
- 2046936817 If A Murderer Kills You, It's Homicide If A Drunk Driver Kills You, It's Manslaughter If the FDA Kills You, It's Just Being Cautious
- 2046936818-6820 Frustration for Medical Innovators
- 2046936821 Block That Innovation
- 2046936822-6823 Getting Even
- 2046936824-6826 Biotech Pipeline: Bottleneck Ahead
- 2046936827-6829 Consuming Interest Are We Safe From the FDA?
- 2046936830-6839 Saying Yes to Drugs Policy Analysis
- 2046936840-6858 Deadly Overcaution: FDA's Drug Approval Process
- 2046936859 B
- 2046936860-6861 Litigation Update Wlf Wins Suit Against FDA to Stop Overregulation of Heart Valves (Washington Legal Foundation V. Shalala)
- 2046936862-6863 Litigation Update Wlf Opposes FDA Efforts to Dismiss First Amendment Lawsuit (Washington Legal Foundation V. Kessler)
- 2046936864-6867 Dickinson's FDA Review
- 2046936868-6869 Wlf Urges Appeals Court to Enjoin Federal Policy Restricting Human Heart Valve Transplant (Washington Legal Foundation V. Shalala)
- 2046936870-6871 FDA Problems Slow US Andas
- 2046936872-6873 Taking the Heat An Aids Patient Champions A Risky Blood Treatment Banned in the U.S.
- 2046936874-6876 New Study Says Breast Implants Are Not A Health Risk
- 2046936877-6878 Wlf Sues FDA to Overturn Policy Restricting Information on Off-Labels Uses of Approved Drugs and Devices (Washington Legal Foundation V. Shalala)
- 2046936879 Ex-Inspector of F.D.A. Is Convicted of Bribery
- 2046936879A FDA Has No Position Yet
- 2046936880-6881 M-D-D-I Reports - 'the Gray Sheet'
- 2046936882 FDA Halts Test on Device That Shows Promise for the Victims of Cardiac Arrest
- 2046936883 Law Concerning Medical Devices Is Often Ignored
- 2046936884 Dairies, Drugs and Accusations
- 2046936884A FDA to Launch Campaign on New Labels for Food
- 2046936885 Probe of Three FDA Officials Sought Industry Ties Before Approval of Bovine Growth Hormone Are at Issue
- 2046936886-6889 Safety First How A Device to Aid in Breast Self-Exams If Kept Off the Market Other Nations Approved It But U.S. Demands Proof Simple Pad Isn't Risky Nine Year Battle with the FDA
- 2046936893-6894 None - A - Day Is the FDA Out to Take Your Vitamin?
- 2046936895 Will A New Government Program Net the Bad Fish?
- 2046936896-6897 FDA Responds to Wlf Petition Regarding Off-Label Drug Use by Indefinitely Postponing Issuance of Regulatory Guidelines
- 2046936898-6905 FDA Research: Overview
- 2046936906-6910 Government Report Finds Levels Safe Pesticide Residues in Your Children's Food
- 2046936911-6912 Wlf Urges FDA to Rescind Policy Restricting Information Flow on Off-Label Uses of Approved Drugs and Devices
- 2046936913 Regulatory Chokehold FDA Red Tape Dooms Transplant Drug
- 2046936914 FDA Called Lax in Overseeing Medical Sterilizers, Disinfectants
- 2046936915 FDA Sets Labeling Rules for Dietary Supplements Nutritional Data, Support for Health Claims Required
- 2046936916 Chemicals That Taint Seafood Concerns Continue Over Safety of Methylmercury Inspection Processes
- 2046936917 Lifesaving Devices Languish at the FDA
- 2046936918-6919 Wlf Sues FDA to Enjoin Federal Policy Restricting Human Heart Valve Transplants (Washington Legal Foundation V. Shalala)
- 2046936920 What's in Food? Answers Differ at 2 Agencies Manufacturers Fight to Keep FDA Label Rules From Encroaching on Ftc Ad Rules
- 2046936921 Reform the FDA
- 2046936922 Legal Beat FDA Approval Shield Firms in Injury Suits
- 2046936923 Water From A Bottle
- 2046936924 Commentary FDA and Our Split Medical Persona
- 2046936925-6926 FDA Assailed for Slow Testing of New Drugs
- 2046936927 Andrews Office Products Capitol Heights, Md (K)
- 2046936928-6947 Statement by David A. Kessler, M.D. Commissioner of Food and Drugs Before the Committee on Energy and Commerce Subcommittee on Health and the Environment U.S. House of Representatives
- 2046936948-6961 Filthy Food,Dubious Drugs, and Defective Devices: the Legacy of FDA's Antiquated Statute A Staff Report
- 2046936962-6968 Gao Reports on FDA-Related Topics 860000 to Present
- 2046936969 D
- 2046936970-6985 Statement by Louis W. Sullivan, M.D. Secretary of Health and Human Services Before the Committee on Labor and Human Resources U.S. Senate on the Final Report of the Advisory Committee on the FDA
- 2046936986-6992 Proposed Remarks of Dr. Charles Edwards Before the Senate Committee on Labor and Human Resources
- Characteristic
- MISS, MISSING PAGES
- Site
- W6
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- fnn65e00
Document Images
GUil ti [lr'; )~tl't'i'
WHO WILL REGULATE
THE REGULATORS?
If you make a mistake, shouldn't you own up?
Not if you're the FDA, EPA, or FTC.
PETER SAMUEL
0 N THE morning of December
13, 1991, teams of agenta rep-
resenting the Food and Drug
Administration (FDA) and the Envi-
ronmFntal Protection Agency (EPA),
accompanied by armed U,S. marehale,
arrived unannounced at the 1iockville,
Maryland, offteAw of Sporicidin Inc,
arid aimultaneously at its contract
manufacturing iiacility in Joni:esborv,
Tenneame. The agents seized prod-
ucta, ordered a etop to eales and ahip-
menta, and 6lod a formal complaint a]-
leging the prnducts were "adulterated
and misbrsuided." They demandcd
that the company recall all its prod-
ucts, and hegan searching and copying
ita records.
Sporicidin is une of several meusufac-
turPrR of spore-killing products baaed
on the chemical glut,araldehyde, which
are used by hospitals, clinics, phyei
cians, and dentists for disinfecting
seneitive. instrumenta and keeping tA-
bles and other surfaces clear of germa,
Until 1977 the dominant diainfectant
was Cidex, a Johnson & JohnNnn prod-
uct that is niainly compoacd of glu-
taraldehyde. However, plain glutaral
dehyde hae several drawbacks: it is
bulky to atore, for many uses it haa to
be heated W work properly, and it
gives off vapors that sting the eyes
and nose and cauA-- skin rasheb.
Robert Schattner, a dentiat in the
Washington, D.C:., area, who had al-
ready invented the well-t.rwwn throat
spray Chlnraseptic, experimented with
ways of overcoming these drawbacks,
He mixed the glutaraldehyda with
phonol, the main ingredient in Chlo-
Afr, ~Satnuel runs t:r+rntrac.k Intarnarional,
an enuironmtntol nawr asrvia.
raseptic. The two turned out to have a
synergistic effect, resulting in a disin-
fectant that was able to kill germs, vi-
ruses, and spores more quickly than
plain glutaraldehyde, end that was
much easier to uee.
He started offering a line of productl+
for sale in the mid 19709, tuider the
Sporicidin name. A number of product
reviews in hospital jourttals found that
the products had all the arivantagea
that Dr. Schattner claimed, Others
dieputed the matter, and there were
various cldime and counterclaims.
Some of these appear to have resulted.
from honest differences of prr,feseional
opinion; others appear to havo ~een
mntivatod by competitive conaidera
tions. In any case, until last December
the Sporicidin producta-a cold etoril-
izing exflution, dieinftxt.ant sprays, dis-
infectant towclottes, and a general
disinfectant aolution-had been used
unchangod since their introduction 14
years ago and had gained nearly a
quarter of the S60-to-a7p-milLian an-
nual market for medical-inatrument
tli9lnfectants.
Normally, regulatorx intervene
when cuatomers are unhappy with a
product, or are incapable of making in-
formed decisions. Yet the uaere of
Sporicidin and other, similar diainfec-
tants are almost ezclusively well-
informed profeeeionale, None of them
had hrpn lodging complaints with the
agencies. The Centers for Disease
Control eays it does not have a recerd
of any case of a disease acquired as a
result of failure of Sporicidin. Ae late
as December 12, 1991, a notarized let-
f.er to Dr. Schattner from John H. Lee,
the product manager of the Antimicrtr
biel Programs Branch of the LPA's Of-
38 3ft NATIONAL REVIEW / NOVEMBER 2, 199(2
Gou of Pesticides and Toxic Sulr
etanres, said Sporicidin was "properl-v
registered and certified" and that it
was approved for aale for the dieinfect-
ing and sterili.zing usdn indicated ou
itp label_
Hut the very next day, the agencies
swung into action. The EPA has regu-
lated such germicides for yeara; lately
the FDA has gained a share of juria-
diction, by defining the dieinfeictant
solutions as "medical devicea." The
Federal Trade Commission also got
into the act by questioning the adver
tiainR claims made for che products.
All three agencides iaHued long preel+
rQleases and gave press briefings aftor
the raid.
For the Prosecutinn
0 NE YH! TEXT for the raid
wae 0 the claim that Sporicidirl
did not have an FDA market-
ing permit (called b10k). This was a
Kafkaeaque comp)aint, since the FDA
had not iaaued any rules aa to how
companlea could obtain such cloar
ances. No clearancee at all had b+jen
obtained by any company for any of
these disinfectant products.
A more serioua-IU,unding claim waft
that Sporicidin producta wPrP ineffec
tive. FDA administrator David Kkwur
ler wxa quoted in a press releasa-
`These products do not work, Doctors,
dentists, and other health profeaaion-
ale ahould stop using them." The FDA
also charged that Sporicidin products
could cause "serious, adveree health
consequences, or death."
The EPA and FTC joined the FDA
in publicly accusing the comPlany of
false and misleading advertising, on
the grounds that FDA lab testl3 had
shown that the Sporicidin products
faileti to sterilize as claimed.
In the months following the F'DAJ
EPA/F"I`C media circus, it transpired
that what is ineffective and a menace
to public health is not the Sporicidin
producta but the guvernrnent teat. ln-
deed, a year before i t participatPd in
the raid, the F.PA formally acknowl
edged serious deficienciea in its teat.
In a request for applicants for a con-
tract to reaearch a replacemunt testing
system, published in the Federal Reg-
tster of December 6, 1990, the EPA
said that the ensting test methods
(the so-called AOAC aporicidal test)
"lack reliability and reproducibility"
and cited ten eerioua technical prob-

t
lems in the test. The ba.ic flaw in the
current test in that it pits diain!'oc-
tsnts being tested againet enormously
varying numbers of eporea--aa few an
a hundrpl in xi,mP cees, as many as a
million in othera, And it is conducted
in small containers of porroeiain with
greatly varying nutnbers of tiny cracks
and fiesurea in which the pathogene
can hido from the disinfectant. tNor
man Miner, a veteran tester at
Johnson & Johnson, said the test was
so unreliable that all products, includ-
ing his own company's Cidex, failed
regularly.l 'I'he EPA subaequently
awarded a f700,U00 research contract
to a Canadian univergity to develop an
improved taet.
The FDA alao knew the test was
flawed, as the July 13 noweletter of
the Chemical Spocialtiea Manufactur
ere Aaacx:iation (CSMA) reporta, Vir-
ginia Chamharlain, the~ person in
charge of dieinfectiao etnd ateriLization
at the FDA's offiee of compliance and
surveillance, eclsnowledgea that the
AOAC aporicidal test io "outdated"
and says the FDA is working to im
prove ite test methode. Tim U7atowsid,
asanciate director of the FDA'a Center
for Devicce and Radiological Nealth,
says. "AOAC methoda are troubte
some." Apparently, however, concern
ebout the inadequacy of the tests at
the working level of the FDA never fil-
tered up to the elevet.d level of the
agency's media-hungry wonderboy,
David Kessler. Or perhaps he doesn't
care?
Day in Court
S PpRICfI)tIN is not the only
manufacturer heing haraesed. A
competitor, Metrex Corporation,
which markets MetriCide (a aimi
lar glutaraldchydc-baaed diainfect-
ant), took the EPA ta court-and hu-
miliated it. Judge Lewi® T. Babcock of
the U.S. District Court in Colo- f
rado concluded on June 18, in
Metnex Corp, v. b6rilliam K Reilly
(the EPA head), that the govern
ment had failed to follow proper
laboratt>ry procedures in teating
MotriCide, thus failing to prop-
erly establish its cane that the
products were ineffective.
The case revealed various
aloppy testing proceduree--over-
diluted Ramples, ineppropriate
documentation. In short, tha F,pA's
teator, an FDA lab in Minneapulis,
failed to adhere to the established code
of Gcxud Labortitory Practices--the
exact kind of negligent behavior for
which it levies fines of hundreds of
thoueanda of dollars againAt outside
laboratories,
Judge Babcock said that in his judg.
ment the EPA's press releases and
hot-line announcemente about the tedt
failures of Metrex products were "as a
u,ata.er of fact and of law false." He or-
dered the EPA to cease ita ptatement.e
and said that it "either knew or should
have known that the results in this
case were not sufficiently reliable to be
called valid."
The tests used to discredit Spnri-
cidin were apparentdy juat aa bad.
They were conduct2d in the aame
food-texting laboratory run by the
FDA in Minneapolis. The FDA teet
data aheete indicate that the Spori
cidin tested may have been Allowed to
age beyond the nabmmended limit,
and may nlRo have baen diluted be-
yond the level for which it is regia-
tutvd. Even so, Sporicidin's cold atcril-
izing solution paa8ed 239 out of 240
teata.
Joseph Knnzelman, clinical director
of oral-health research at the Walter
Reed Army Medical Center, testified
that his review of the tests on Spori-
cidin persuaded him they were im-
properly conducted, and said he re-
garded the FDA report ae misleading.
What of the dramatic I)ecember 13
charge that Sporicidin was "adulter-
ated"? It turne out this allegation
arotw from the regulators' innocence of
basic chetniatry. They had noticed a
discrepancy between the list of conetit-
uente on the label and the nwnuPac-
turing formula. Sodium phenate,
which the product label names as a
constituent, does not appear on factory
invoicca. What they did not know was
tn
Yr.
that sodium phenate is nbtained by
mixing sodium hydroxide and phenol.
Look!!!g-Ir14SS 1 c7gic
F IVE MONTHS after the denun-
j/ ciation of Sporicidin'a products,
the FDA quiPtly signed an
agreement with E3poricidin allowing
several of the products which Admin-
istrator Keaaler had said wero "inef-
fective" and "adulterated" back on the
market without any change whatever
in their formulation,
In the consent agreement between
Sporicldin and the FDA, the company
agreed to what the H'L)A chose to call
a ',econditioning' of its product. "Re-
conditioning" usually means that the
product irs reworked to change its com-
position and charactcriatica. In this
caae, it refers solely to the inaertion of
an extra instruction sheet in the pack-
aginR. This misleading language ie
part of the FDA'e coverup, an attempt
to claim that the agency forced the
company to correct deficiencies in its
product, rather than admit that there
wero no deficinnciee.
Moreover, the FDA haa Also insidted
thP company destroy rcprinta uf acien-
tificjournal articles that touch on its
products. FDA officem have demanded
to supervise the dumping of boxoe full
of articles on gluttrraldehydebased
distnfectmnta publiahed in The Journnl
of dpernting Hoom 1teAearch, The
Journbl of Clinical Micmbiology, and
auchlike.
At the time uf writing the EPA ia
still holding out on Sporicidin with
some bizarre maneuvers of its own, ot-
fering to lift its freezP on Sporicidin's
cold sterilizing solution-which the
EPA had repeatedly approved before
December 13---only if Sporicidin does
its own laboratory teating to dcmon-
strate the product's efficacy.
So we have reached the eituation
--~ whore the FDA has allowed prod-
neutralizing rwlutions, failure to "You'm
use control aamplta--and poor
big trouble, fella--you ie trespa.eaueg
on u/JYcial gouerntnerst wetland"
4.0 NATIUNA(. REVIEW / NOVEMSF.k 2. 1992
ucts back on the marktt which
David Kessler naid last year
"don't work." The old AOAC test
is diacredited, and therc is no
generally accepted teet to dem
onatrate spore-killing power. The
EYA, as we have seen, already
haa research contractm out with
a Canadian company for an im-
proved lest, but now it wants a
small private company to pasa
a completely new battery of teata
laAting many rnunth® while its

0
products remain banned on the baaie
of tht diecrcditod test.
Only in Amorica.
SporScidin est{matea itu ltsses to the
end of July at more than $10 million-
$5 million in lost sales, $2 million in
customer reimbursemente, $1 million
in legal fees, and $2 million in lost in-
ventory. Thirty people in the manu.fuc-
turing plant lost their jobs, and a
dozen administrative and ealea people
have gono. In their place, a team of
ltlwytrM.
Agencies that are Qnppoaedly dedi-
cated to serving public health aro en-
dangering it by spreading disinforma-
tion, disrupting the supply chain for
diainfectanta, and heavily aeaaulting
the economic viabi2ity of the aompa
niee that manutacture them. Two of
these have been farced clcm. to bank-
ruptcy for no good rea8on. Another,
3M, has withdrawn from the market.
opting "not to get bogged down in the
Federal Government'e regulatory proc-
eas." The regulator8 are adding a mas-
sive riak premium te the calculations
uf anyone doing business in territory
where the government gangs roam.
What i® behind this destructive
madness? Several agencies fighting for
regulatory turf? A drive by regulatorn
to jutiify their budget claims in Con-
.\u Si,,;;lc' I~~rtc
gteea? Nursn$1 Waahington hlunder-
ing? Perhaps a bit of all of these. O
THE ABORTION WAR
The paradox: Most Americans are 'pro-choice'-
and yet they oppose most of the abortions pcrformed.
MARK Ci1NNIM6KAA1
T HE PRO-LIFE movement is on
the ropes. The Supreme Court
has affirmed the central tenets
of Roe v. Wade and embraced the cnn.
cept of radical individualism that is at
the center of the pro-choice poaition.
President Bush, who has held the line
on abortion even though he cannot
present a coherent defense of hiy view,
is likely to be replaced by Governor
Mr. Cutminghunc ia NR's Articlea Edaor.
Clinton, whose Administration will
surely emhrace l4nlation tu roll beck
the modest restrictions the Gourt al-
lnwed in f'lanned Parenthood v. Casey.
Are there any anneta remaining to
thoae who resist the transformation of
abortion into a positive good? What
atrategiea ought they to follow?
First of all, there is considerable re-
sietance to the actual practice of abor-
tion. Though the AMA abandonod for-
mal opposition decades ago, abortion
is nonetheless fenced off within the
medical community. At U.S. medical
sehoolt, only a quarter of ohlgym reai-
dency programs require abortion
training, and another quarter dnn't
offer it all; participation in the op-
tional programs is low. (How many
mothers dream of someday preaenting
"my son the abortionist"?) In 1990,
according to the Waahingwn t'cusr!,
"roughly eight thnusand 1R,OQ0?j phya-
iciene performed mnat of the 1.6 mil-
lion abortions in the United States
. Roughly 70 per cent of those abor-
tions are performed at 300 clinics."
Outpatient clinics performed 4,6 per
cent of abortions in 1973, 86 per cent
in 19R8. The atAndards vary from the
relativety posh and professional Rerv-
icea of Planned Parenthood to what
are quita fairly cAllFSd "abortion milla,"
places even the n,unt z,ea.loua pro-
ehoicero are ashamed to defend.
Activist pro-choicers are up in arms
over the fact that B3 per cent of the
3,135 Counties in the U.S. have no fa-
cilitiee for abortion. The numberu are
deceptive, since the more populous
eountiee are full of clinics, and it is no
great burden for moat people to reach
the neareat good-sized city. Still, this
auggeatA that community sentiment
~ --
Th£} :ay we are "drifting."
s:F41-- .- , -,,=
Th'.i~'~fay we "lack a cause"
I
txi:ine meet a few
ttiand who disagree.
M
MEN
0
rican Collegians for Life
f.!
Training Conference
nnual National Leadership
2-24, 1993 Washington, DC
A~a
ff'Cbnference- f3ux 1840, Fairfield Univ.
0!
[;CT 064:1p - Or Call Z03-?54-y1 U3
Mm
42 NATIf.)NAL N.EViE,W ; TlUVEMAER 2, 1992
